# US 2016/0256467 A1 · Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256467 A1
- Document ID: US20160256467A1
- Status: Published application
- Kind: A1
- Application number: 15/152,703
- Filed: 2016-05-12
- Published: 2016-09-08
- Earliest claimed: 2013-03-15
- Applicants: Shifa Biomedical Corporation
- Inventors: Sherin Salaheldin Abdel-Meguid; Nabil Elshourbagy; Harold Meyers; Shaker A. Mousa
- Web page: https://patentgrep.com/patent/US20160256467A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/415: 1,2-Diazoles
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/42: Oxazoles
- A61K 31/426: 1,3-Thiazoles
- A61K 31/433: Thidiazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61P 3/06: Antihyperlipidemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia. Examples of compounds include thiadiazole, isoxazole, 1,2,4-triazole, thiazole, indole, pyrazole, and pyrrolinone derivatives.

## Claims

### Claim 1

A method for treating or preventing hypercholesterolemia, and/or at least one symptom of dyslipidemia, atherosclerosis, CVD or coronary heart disease in a patient in need of said treatment, the method comprising administering a therapeutically effective amount of a compound of the formula:
wherein A is selected from the group consisting of:
wherein R1, R2, and R3 are independently selected from the group consisting of H and, optionally substituted, lower alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle and heteroaryl; R4 is selected from the group consisting of H, lower alkyl, OH, SH, NH2, halo, CN, carboxyl, amido and carboxamido;
X is (CH2)n, O, S, N(R5) or a valence bond; R5 is H or lower alkyl; and n is an integer from 1 to 3;
M is CONH, NHCO, NHSO2, NHCON(R6) or a valence bond; R6 is H or lower alkyl;
Q is independently CH or N;
Z is CH2, S, O, or NH;
m and p are independently an integer from 0 to 1;
B is selected from the group consisting of C(═O) and S(═O)2;
T is selected from the group consisting of H, amino, alkoxy, carboxy, amido, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, monoalkylaminosulfinyl, dialkylaminosulfinyl, monoalkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, hydroxysulfonyloxy, alkoxysulfonyloxy, alkylsulfonyloxy, hydroxysulfonyl, alkoxysulfonyl, alkylsulfonylalkyl, monoalkylaminosulfonylalkyl, dialkylaminosulfonylalkyl, monoalkylaminosulfinylalkyl, dialkylaminosulfinylalkyl and, optionally substituted, lower alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, and heteroaryl;
Ra and Rb independently represent H or lower alkyl, and t, u, v and w are independently an integer from 0 to 1 with the proviso that at least one of v and w is 0;
and the pharmaceutically acceptable salts and all stereoisomers of the compound.

### Claim 2 (depends on 1)

The method of claim 1, wherein said patient is administered at least one compound of the formula:
wherein Het is selected from the group of
and R2 is optionally substituted alkyl, cycloalkyl, aralkyl, aryl, heterocycle, heterocycloalkyl, heteroaryl, and heteroarylalkyl, X is selected from the group of NRc, O, S, and a valence bond to R1, and Rc is H or lower alkyl;
Z is selected from the group of S, O, and CH2;
R1 is selected from the group of optionally substituted alkyl, cycloalkyl, aryl, aralkyl, heterocycle, heterocycloalkyl, heteroaryl, and heteroaralkyl;
Ra, Rb, R′ and R″ are independently selected from the group of H and lower alkyl;
X1, Y1 and Z1 are the same or different and each represents hydrogen or a substituent from the group consisting of hydroxyl, halogen, amino, monoalkylamino, dialkylamino, alkoxy, carboxy, amido (including formamido, alkylamido and arylamido), aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, carbamato, carboxamido, monoalkylaminosulfinyl, dialkylaminosulfinyl, monoalkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, hydroxysulfonyloxy, alkoxysulfonyloxy, alkylsulfonyloxy, hydroxysulfonyl, alkoxysulfonyl, alkylsulfonylalkyl, monoalkylaminosulfonylalkyl, dialkylaminosulfonylalkyl, monoalkylaminosulfinylalkyl, dialkylaminosulfinylalkyl and, optionally substituted, lower alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, and heteroaryl;
and s, t and u are independently an integer from 0 to 1;

### Claim 3 (depends on 1)

The method of claim 1, wherein said patient is administered at least one compound of the formula:
wherein T is selected from the group of optionally substituted alkyl, aralkyl, aryl, heterocycle, heterocycloalkyl, heteroaryl, and heteroarylalkyl; R3 is selected from the group of optionally substituted alkyl, aralkyl, aryl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
Ra and Rb are independently selected from the group of H and lower alkyl.

### Claim 4 (depends on 1)

The method of claim 1, wherein said patient is administered at least one compound of the formula:
wherein T and R3 are independently selected from the group of optionally substituted cycloalkyl, aryl, heterocycle, and heteroaryl;
and Ra and Rb are independently selected from the group of H and lower alkyl.

### Claim 5

(canceled)
